199 related articles for article (PubMed ID: 38230747)
21. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
22. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
23. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling.
Zhang Y; Lin CHS; Kaushansky K; Zhan H
Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133
[TBL] [Abstract][Full Text] [Related]
24. mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.
Bogani C; Bartalucci N; Martinelli S; Tozzi L; Guglielmelli P; Bosi A; Vannucchi AM;
PLoS One; 2013; 8(1):e54826. PubMed ID: 23382981
[TBL] [Abstract][Full Text] [Related]
25. Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy.
Brkic S; Stivala S; Santopolo A; Szybinski J; Jungius S; Passweg JR; Tsakiris D; Dirnhofer S; Hutter G; Leonards K; Lischer HEL; Dettmer MS; Neel BG; Levine RL; Meyer SC
Leukemia; 2021 Oct; 35(10):2875-2884. PubMed ID: 34480104
[TBL] [Abstract][Full Text] [Related]
26. Circulating CD133+/–CD34– Have Increased c-
Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
[TBL] [Abstract][Full Text] [Related]
27. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.
Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H
J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974
[TBL] [Abstract][Full Text] [Related]
28. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
29. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders.
Levine RL; Wernig G
Hematology Am Soc Hematol Educ Program; 2006; ():233-9, 510. PubMed ID: 17124066
[TBL] [Abstract][Full Text] [Related]
30. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation.
Sun T; Zhang L
Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442
[TBL] [Abstract][Full Text] [Related]
31. Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.
Gou P; Zhang W; Giraudier S
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162937
[TBL] [Abstract][Full Text] [Related]
32. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Gou P; Liu D; Ganesan S; Lauret E; Maslah N; Parietti V; Zhang W; Meignin V; Kiladjian JJ; Cassinat B; Giraudier S
Blood Cancer J; 2024 Jan; 14(1):1. PubMed ID: 38177095
[TBL] [Abstract][Full Text] [Related]
33. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
Chen YX; Li Y; Zhang LY; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
[TBL] [Abstract][Full Text] [Related]
34. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
35. AKT is a therapeutic target in myeloproliferative neoplasms.
Khan I; Huang Z; Wen Q; Stankiewicz MJ; Gilles L; Goldenson B; Schultz R; Diebold L; Gurbuxani S; Finke CM; Lasho TL; Koppikar P; Pardanani A; Stein B; Altman JK; Levine RL; Tefferi A; Crispino JD
Leukemia; 2013 Sep; 27(9):1882-90. PubMed ID: 23748344
[TBL] [Abstract][Full Text] [Related]
36. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice.
Yan D; Jobe F; Hutchison RE; Mohi G
Leukemia; 2015 Oct; 29(10):2050-61. PubMed ID: 26044284
[TBL] [Abstract][Full Text] [Related]
37. Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Liu PC; Caulder E; Li J; Waeltz P; Margulis A; Wynn R; Becker-Pasha M; Li Y; Crowgey E; Hollis G; Haley P; Sparks RB; Combs AP; Rodgers JD; Burn TC; Vaddi K; Fridman JS
Clin Cancer Res; 2009 Nov; 15(22):6891-900. PubMed ID: 19887489
[TBL] [Abstract][Full Text] [Related]
38. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
39. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
Gorantla SP; Dechow TN; Grundler R; Illert AL; Zum Büschenfelde CM; Kremer M; Peschel C; Duyster J
Blood; 2010 Nov; 116(22):4600-11. PubMed ID: 20696946
[TBL] [Abstract][Full Text] [Related]
40. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]